Relationships between auditory event-related potentials and mood state, medication, and comorbid psychiatric illness in patients with bipolar disorder.

Publisher: Wiley-Blackwell Munksgaard Country of Publication: Denmark NLM ID: 100883596 Publication Model: Print Cited Medium: Internet ISSN: 1399-5618 (Electronic) Linking ISSN: 13985647 NLM ISO Abbreviation: Bipolar Disord Subsets: MEDLINE

Publication: Copenhagen : Wiley-Blackwell Munksgaard
Original Publication: Copenhagen, Denmark : Munksgaard, 1999-

Bipolar Disorder*/drug therapy ; Bipolar Disorder*/physiopathology; Antipsychotic Agents/*therapeutic use ; Evoked Potentials, Auditory/*physiology ; Mental Disorders/*drug therapy ; Mood Disorders/*complications; Acoustic Stimulation/methods ; Adult ; Analysis of Variance ; Electroencephalography/methods ; Evoked Potentials, Auditory/drug effects ; Female ; Humans ; Male ; Middle Aged ; Mood Disorders/drug therapy ; Neuropsychological Tests ; Psychiatric Status Rating Scales ; Reaction Time/physiology ; Regression Analysis

Background: Patients with bipolar disorder (BD) exhibit aberrations in auditory event-related potentials (ERPs), although the relationships between these measures and mood state at testing, comorbid psychiatric illness, presence of psychotic features, and medication usage are unclear. The purpose of this study was to investigate the relationships between these factors and auditory ERP measures in BD patients.
Methods: An auditory 'oddball' discrimination task was used to elicit ERPs from 69 patients with type I BD and 52 healthy controls. Patients were placed into subgroups based upon their mood state at testing (euthymic or symptomatic), and ANOVA was used to compare amplitude and peak latency measures from the N100, P200, N200, and P300 ERP components across subgroups. Multiple regression was used to investigate relationships between ERP measures and comorbid psychiatric diagnosis, history of psychotic features, and medication status.
Results: Relative to healthy control participants, euthymic and symptomatic BD patients exhibited reduced P300 and P200 amplitude, but ERP measures did not differ among BD patients on the basis of mood status. A history of a comorbid anxiety disorder was associated with reduced N200 peak latency, but prolonged P300 peak latency among BD patients. No other relationships between clinical variables and ERP measures were significant.
Conclusions: The results suggest that disrupted auditory attention may be observed in BD patients regardless of their mood state at testing, medication status, or history of psychosis. These results extend previous findings, and provide further evidence for aberrations in the P300 ERP as an endophenotype for BD.

J Affect Disord. 2002 Dec;72(3):209-26. (PMID: 12450638)
Int J Psychophysiol. 2004 Jun;53(1):45-55. (PMID: 15172135)
Annu Rev Clin Psychol. 2006;2:267-90. (PMID: 17716071)
Psychophysiology. 1999 Nov;36(6):667-82. (PMID: 10554581)
Neuropsychobiology. 2004;50(2):167-73. (PMID: 15292673)
Arch Gen Psychiatry. 1998 Feb;55(2):173-80. (PMID: 9477932)
Bipolar Disord. 2008 May;10(3):377-86. (PMID: 18402626)
Alcohol Clin Exp Res. 2001 Sep;25(9):1293-300. (PMID: 11584148)
Psychophysiology. 2003 Sep;40(5):684-701. (PMID: 14696723)
Clin Neurophysiol. 2001 Aug;112(8):1508-15. (PMID: 11459691)
Biol Psychiatry. 1999 Jan 1;45(1):98-106. (PMID: 9894581)
J Med Genet. 2005 Mar;42(3):193-204. (PMID: 15744031)
Schizophr Bull. 2008 Jul;34(4):760-73. (PMID: 18502737)
Am J Psychiatry. 2003 Apr;160(4):636-45. (PMID: 12668349)
Psychol Med. 2000 May;30(3):545-55. (PMID: 10883710)
J Clin Neurophysiol. 1998 Jan;15(1):44-57. (PMID: 9502512)
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1387-92. (PMID: 17628288)
Biol Psychiatry. 1995 Mar 1;37(5):300-10. (PMID: 7748981)
Psychiatry Clin Neurosci. 2005 Feb;59(1):83-8. (PMID: 15679545)
Br J Psychiatry. 1978 Nov;133:429-35. (PMID: 728692)
Int J Psychophysiol. 2006 May;60(2):172-85. (PMID: 16510201)
Psychophysiology. 1992 Jul;29(4):398-411. (PMID: 1410172)
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):123-6. (PMID: 11853102)
Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788)
Psychol Med. 2007 May;37(5):667-78. (PMID: 17224092)
Schizophr Res. 1991 Mar-Apr;4(2):209-31. (PMID: 2039762)
Biol Psychiatry. 1996 May 15;39(10):845-56. (PMID: 9172705)
Psychosom Med. 2005 Jan-Feb;67(1):1-8. (PMID: 15673617)
Am J Med Genet. 2002 May 8;114(4):391-406. (PMID: 11992561)
Science. 1981 Jan 2;211(4477):77-80. (PMID: 7444452)
Int J Psychophysiol. 1994 Aug;17(3):219-31. (PMID: 7806466)
Phys Med Rehabil Clin N Am. 2004 Feb;15(1):133-61. (PMID: 15029903)
J Affect Disord. 2005 Apr;85(3):301-15. (PMID: 15780700)
J Clin Neurophysiol. 1998 Jan;15(1):14-33. (PMID: 9502510)
Psychol Med. 1991 Nov;21(4):867-79. (PMID: 1780401)
Schizophr Bull. 2010 Sep;36(5):991-1000. (PMID: 19282472)
Acta Psychiatr Scand. 1998 Dec;98(6):459-66. (PMID: 9879788)
Biol Psychol. 2002 Oct;61(1-2):111-38. (PMID: 12385672)
Biol Psychiatry. 1994 Aug 1;36(3):153-70. (PMID: 7948453)
Schizophr Bull. 2007 Jul;33(4):932-6. (PMID: 17575303)
Eur Arch Psychiatry Clin Neurosci. 1997;247(2):107-11. (PMID: 9177958)
Neuropsychologia. 1992 Aug;30(8):723-41. (PMID: 1407488)
Am J Psychiatry. 1997 Sep;154(9):1320-1. (PMID: 9286204)
Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84. (PMID: 6187540)

R01 MH62150-01 United States MH NIMH NIH HHS; T32 MH17146 United States MH NIMH NIH HHS; R01 MH074983 United States MH NIMH NIH HHS; T32 MH017146 United States MH NIMH NIH HHS; R01 MH062150 United States MH NIMH NIH HHS; R03-MH63112-01 United States MH NIMH NIH HHS

0 (Antipsychotic Agents)

Date Created: 20091120 Date Completed: 20100127 Latest Revision: 20211020

20240829

PMC4655591

10.1111/j.1399-5618.2009.00758.x

19922554